Tr1x Bio

NEWS
The San Diego-based startup, specializing in allogeneic engineered Treg and CAR-Treg cell therapies, plans to be in Phase I clinical trials in multiple indications in 2024.
IN THE PRESS
Tr1X, Inc. announced its emergence from stealth with a $75 million Series A financing to bring universal allogeneic regulatory T and CAR-Treg cell therapies to the clinic to treat and potentially cure autoimmune and inflammatory diseases.